Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against Klebsiella pneumoniae Carbapenemase- and Extended-Spectrum-β-Lactamase-Producing Enterobacter Species
- 1 September 2016
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 60 (9), 5208-5214
- https://doi.org/10.1128/aac.00869-16
Abstract
We compared the in vitro activities of gentamicin (GEN), tobramycin (TOB), amikacin (AMK), and plazomicin (PLZ) against 13 Enterobacter isolates possessing both Klebsiella pneumoniae carbapenemase and extended-spectrum β-lactamase (KPC+/ESBL+) with activity against 8 KPC+/ESBL−, 6 KPC−/ESBL+, and 38 KPC−/ESBL− isolates. The rates of resistance to GEN and TOB were higher for KPC+/ESBL+ (100% for both) than for KPC+/ESBL− (25% and 38%, respectively), KPC−/ESBL+ (50% and 17%, respectively), and KPC−/ESBL− (0% and 3%, respectively) isolates. KPC+/ESBL+ isolates were more likely than others to possess an aminoglycoside-modifying enzyme (AME) (100% versus 38%, 67%, and 5%; P = 0.007, 0.06, and P < 0.01 for all). KPC+/ESBL+ isolates also had a greater number of AMEs (mean of 4.6 versus 1.5, 0.9, and 0.05, respectively; P < 0.01 for all). GEN and TOB MICs were higher against isolates with >1 AME than with ≤1 AME. The presence of at least 2/3 of KPC, SHV, and TEM predicted the presence of AMEs. PLZ MICs against all isolates were ≤4 μg/ml, regardless of KPC/ESBL pattern or the presence of AMEs. In conclusion, GEN and TOB are limited as treatment options against KPC+ and ESBL+ Enterobacter . PLZ may represent a valuable addition to the antimicrobial armamentarium. A full understanding of AMEs and other aminoglycoside resistance mechanisms will allow clinicians to incorporate PLZ rationally into treatment regimens. The development of molecular assays that accurately and rapidly predict antimicrobial responses among KPC- and ESBL-producing Enterobacter spp. should be a top research priority.Keywords
Funding Information
- HHS | National Institutes of Health (K08AI114883)
- HHS | National Institutes of Health (R21AI11103)
- HHS | National Institutes of Health (R21AI123747)
This publication has 48 references indexed in Scilit:
- Rise and dissemination of aminoglycoside resistance: the aac(6′)-Ib paradigmFrontiers in Microbiology, 2013
- Prevalence of Plasmid-Mediated Quinolone Resistance and Aminoglycoside Resistance Determinants among Carbapeneme Non-Susceptible Enterobacter cloacaePLOS ONE, 2012
- Activity of Plazomicin (ACHN-490) against MDR clinical isolates ofKlebsiella pneumoniae, Escherichia coli, andEnterobacterspp. from Athens, GreeceJournal of Chemotherapy, 2012
- A carbapenem-resistant Klebsiella pneumoniae epidemic clone in Jerusalem: sequence type 512 carrying a plasmid encoding aac(6')-IbJournal of Antimicrobial Chemotherapy, 2012
- Aminoglycoside Susceptibility Profiles of Enterobacter cloacae Isolates Harboring the aac(6´)-Ib GeneAnnals of Laboratory Medicine, 2011
- A Novel Gene Cassette, aacA43 , in a Plasmid-Borne Class 1 IntegronAntimicrobial Agents and Chemotherapy, 2011
- Aminoglycoside modifying enzymesDrug Resistance Updates, 2010
- Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 and ArmA 16S rRNA methylase conferring high-level aminoglycoside resistance in carbapenem-resistant Enterobacter cloacae in ChinaDiagnostic Microbiology and Infectious Disease, 2010
- Development of a set of multiplex PCR assays for the detection of genes encoding important β-lactamases in EnterobacteriaceaeJournal of Antimicrobial Chemotherapy, 2010
- Genetic Organization of Transposase Regions Surrounding bla KPC Carbapenemase Genes on Plasmids from Klebsiella Strains Isolated in a New York City HospitalAntimicrobial Agents and Chemotherapy, 2009